by Lisa Willemse | Dec 6, 2013
> To be, or not to be, that is the question: Whether ’tis Nobler in the mind to suffer The Slings and Arrows of outrageous Fortune, Or to take Arms against a Sea of troubles, And by opposing end them We know this famous soliloquy from Shakespeare’s...
by Nick Dragojlovic | Dec 2, 2013
> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of...
by Mark Curtis | Nov 27, 2013
. Welcome to the regenerative medicine deal review for the month of November. Cytori Therapeutics and Lorem Vascular have teamed up to catalyze the commercialization of Cytori cell therapies using its proprietary Celution® System in Asia. There was also a notable deal...
by Lisa Willemse | Apr 25, 2013
Co-authored with Geoff Lomax, CIRM’s Senior Officer to the Standards Working Group from the “Understanding Stem Cell Controversies” Workshop organized by the Stem Cell Network in Montreal. This article is cross-posted on the CIRM blog. The afternoon session on Day 2...
by Nick Dragojlovic | Feb 20, 2013
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is...
Comments